You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 吉貝爾升超8% 抗抑鬱新藥已完成I期臨牀研究
格隆匯 09-11 10:15
吉貝爾(688566.SH)升超8%,報27.5元,總市值52億元。吉貝爾近期接受投資者調研時稱,公司抗抑鬱新藥JJH201501現已完成I期臨牀研究,正在開展IIb期臨牀試驗,已按照方案要求,完成全部受試者入組,共計308例,正在進行隨訪觀察和數據處理,其I期臨牀試驗中,和對照藥物的單次給藥PK結果顯示,抗抑鬱新藥JJH201501在t1/2、Cmax、AUC以及主要代謝物的AUC等PK參數上均比對照藥物表現出明顯的優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account